RECBIO's new drug application for REC610 has been accepted

AASTOCKS
2025.12.29 16:47

RECBIO-B (02179.HK) announced that the new drug application for its adjuvanted recombinant herpes zoster vaccine REC610 has been officially accepted by the Center for Drug Evaluation of the National Medical Products Administration. Currently, the only adjuvanted recombinant herpes zoster vaccine available globally is GlaxoSmithKline's Shingrix

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer